用于诊断慢性炎症性疾病的识别半乳糖缺陷 IgG 的抗体 42B1 的生成和验证。

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2024-11-16 DOI:10.1016/j.cca.2024.120052

Naoki Morishima , Maki Iwaisako , Yoshihiro Kamada , Miyako Nakano , Masafumi Shiida , Tatsuya Ono , Reika Sonoda , Risa Uemura , Daisuke Sakon , Munefumi Shimosaka , Shinji Takamatsu , Jumpei Kondo , Takeo Yoshihara , Shinichiro Shinzaki , Eiji Mita , Tetsuo Takehara , Takashi Kumada , Makoto Yamada , Eiji Miyoshi

{"title":"用于诊断慢性炎症性疾病的识别半乳糖缺陷 IgG 的抗体 42B1 的生成和验证。","authors":"Naoki Morishima , Maki Iwaisako , Yoshihiro Kamada , Miyako Nakano , Masafumi Shiida , Tatsuya Ono , Reika Sonoda , Risa Uemura , Daisuke Sakon , Munefumi Shimosaka , Shinji Takamatsu , Jumpei Kondo , Takeo Yoshihara , Shinichiro Shinzaki , Eiji Mita , Tetsuo Takehara , Takashi Kumada , Makoto Yamada , Eiji Miyoshi","doi":"10.1016/j.cca.2024.120052","DOIUrl":null,"url":null,"abstract":"<div><div>Galactose-deficient (agalactosyl) IgG is significantly increased in the serum of patients with rheumatoid arthritis, and autoantibodies against it are used in clinical tests. Subsequent studies also show increased agalactosyl IgG in many chronic inflammatory diseases. In this study, we generated antibody 42B1 recognizing agalactosyl IgG and developed a new method to evaluate chronic inflammatory diseases with it. Using an ELISA with antibody 42B1, we measured serum levels of agalactosyl IgG in 32 patients with inflammatory bowel disease (IBD), 60 patients with chronic liver disease, 60 patients with chronic pancreatitis, and 32 subjects undergoing health checkups who did not have IBD. Serum agalactosyl IgG levels were increased in all patients with chronic inflammations and partially correlated with clinical parameters. Among the subjects undergoing health checkups, some subjects showed a 15 % elevation of serum agalactosyl IgG levels, suggesting possible latent chronic inflammation. Future studies will examine the 42B1 antibody ELISA in various autoimmune diseases. Altogether, the 42B1 antibody for determination of serum agalactosyl IgG levels is a novel diagnostic tool for chronic inflammation.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"566 ","pages":"Article 120052"},"PeriodicalIF":3.2000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Generation and validation of antibody 42B1 recognizing galactose-deficient IgG for diagnosis of chronic inflammatory diseases\",\"authors\":\"Naoki Morishima , Maki Iwaisako , Yoshihiro Kamada , Miyako Nakano , Masafumi Shiida , Tatsuya Ono , Reika Sonoda , Risa Uemura , Daisuke Sakon , Munefumi Shimosaka , Shinji Takamatsu , Jumpei Kondo , Takeo Yoshihara , Shinichiro Shinzaki , Eiji Mita , Tetsuo Takehara , Takashi Kumada , Makoto Yamada , Eiji Miyoshi\",\"doi\":\"10.1016/j.cca.2024.120052\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Galactose-deficient (agalactosyl) IgG is significantly increased in the serum of patients with rheumatoid arthritis, and autoantibodies against it are used in clinical tests. Subsequent studies also show increased agalactosyl IgG in many chronic inflammatory diseases. In this study, we generated antibody 42B1 recognizing agalactosyl IgG and developed a new method to evaluate chronic inflammatory diseases with it. Using an ELISA with antibody 42B1, we measured serum levels of agalactosyl IgG in 32 patients with inflammatory bowel disease (IBD), 60 patients with chronic liver disease, 60 patients with chronic pancreatitis, and 32 subjects undergoing health checkups who did not have IBD. Serum agalactosyl IgG levels were increased in all patients with chronic inflammations and partially correlated with clinical parameters. Among the subjects undergoing health checkups, some subjects showed a 15 % elevation of serum agalactosyl IgG levels, suggesting possible latent chronic inflammation. Future studies will examine the 42B1 antibody ELISA in various autoimmune diseases. Altogether, the 42B1 antibody for determination of serum agalactosyl IgG levels is a novel diagnostic tool for chronic inflammation.</div></div>\",\"PeriodicalId\":10205,\"journal\":{\"name\":\"Clinica Chimica Acta\",\"volume\":\"566 \",\"pages\":\"Article 120052\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-11-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica Chimica Acta\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0009898124023052\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898124023052","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在类风湿性关节炎患者的血清中，缺半乳糖（半乳糖醛酸）IgG 明显增加，针对它的自身抗体被用于临床检测。随后的研究也表明，在许多慢性炎症性疾病中，半乳糖醛酸 IgG 也会增加。在这项研究中，我们生成了能识别 agalactosyl IgG 的抗体 42B1，并开发了一种用它来评估慢性炎症性疾病的新方法。我们使用抗体 42B1 酶联免疫吸附法测定了 32 名炎症性肠病（IBD）患者、60 名慢性肝病患者、60 名慢性胰腺炎患者和 32 名未患 IBD 的健康体检者的血清中半乳糖基 IgG 的水平。所有慢性炎症患者的血清琼脂糖基 IgG 水平都有所升高，并且与临床参数存在部分相关性。在接受健康检查的受试者中，一些人的血清中的 agalactosyl IgG 水平升高了 15%，这表明可能存在潜在的慢性炎症。未来的研究将检验 42B1 抗体 ELISA 在各种自身免疫性疾病中的应用。总之，用 42B1 抗体测定血清中的 agalactosyl IgG 水平是一种新型的慢性炎症诊断工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Generation and validation of antibody 42B1 recognizing galactose-deficient IgG for diagnosis of chronic inflammatory diseases

查看原文本刊更多论文

Generation and validation of antibody 42B1 recognizing galactose-deficient IgG for diagnosis of chronic inflammatory diseases

Galactose-deficient (agalactosyl) IgG is significantly increased in the serum of patients with rheumatoid arthritis, and autoantibodies against it are used in clinical tests. Subsequent studies also show increased agalactosyl IgG in many chronic inflammatory diseases. In this study, we generated antibody 42B1 recognizing agalactosyl IgG and developed a new method to evaluate chronic inflammatory diseases with it. Using an ELISA with antibody 42B1, we measured serum levels of agalactosyl IgG in 32 patients with inflammatory bowel disease (IBD), 60 patients with chronic liver disease, 60 patients with chronic pancreatitis, and 32 subjects undergoing health checkups who did not have IBD. Serum agalactosyl IgG levels were increased in all patients with chronic inflammations and partially correlated with clinical parameters. Among the subjects undergoing health checkups, some subjects showed a 15 % elevation of serum agalactosyl IgG levels, suggesting possible latent chronic inflammation. Future studies will examine the 42B1 antibody ELISA in various autoimmune diseases. Altogether, the 42B1 antibody for determination of serum agalactosyl IgG levels is a novel diagnostic tool for chronic inflammation.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.